CMS May Take Studious Approach To Covering ESAs In Cancer Setting
Executive Summary
CMS is seeking public input on whether Medicare should respond to safety concerns about the use of erythropoiesis-stimulating agents in cancer patients by paying for ESAs only within the context of clinical studies
You may also be interested in...
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances